Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.6400 (-0.86%) ($12.4500 - $12.7500) on Wed. Jul. 24, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.96% (three month average) | RSI | 50 | Latest Price | $12.6400(-0.86%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.1% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.48% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-15%) IFRA(-10%) TIP(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.48% (StdDev 2.96%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
5 Day Moving Average | $12.82(-1.4%) | 10 Day Moving Average | $12.67(-0.24%) | 20 Day Moving Average | $12.43(1.69%) | To recent high | -11.1% | To recent low | 15.3% | Market Cap | $3.264b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |